Healius Ltd Locks in $45M Annual Pathology Revenue at 13 Ramsay Hospitals
Healius locks in $45m annual pathology revenue under new Ramsay agreement framework
Healius Limited (ASX: HLS) has entered a national agreement framework with wholly-owned subsidiaries of Ramsay Health Care Limited (ASX: RHC), effective 1 July 2026. The arrangement renews and transitions Healius’ existing pathology leases and service arrangements into a uniform set of agreements, rather than representing a new contract win.
Healius is the incumbent provider of pathology services at 13 hospitals operated by Ramsay across NSW, WA, VIC and QLD. Under the framework, there is no change to Healius’ pathology services at those hospitals.
Total annual revenue under the initial terms is expected to be approximately $45m, based on continued customer demand consistent with no significant changes in economic conditions. The new agreements carry initial terms of between two and five years.
When big ASX news breaks, our subscribers know first
What the new national framework covers
The framework consolidates a patchwork of existing leases and service arrangements into one uniform set of agreements across the Ramsay subsidiaries. For Healius, the day-to-day delivery of pathology remains unchanged, with the same services provided at the same hospitals under standardised contracting.
The commercial structure features initial terms of between two and five years. This continuity-focused arrangement maintains Healius’ incumbent position while simplifying how its arrangements with Ramsay are documented across four states.
The 13 hospitals across four states
The hospital footprint spans four states, with the largest concentration in Victoria. All contracts are held by Healius Pathology Pty Ltd (ACN 007 190 043).
-
VIC (7): Beleura, Linacre, Masada, Peninsula, Shepparton, Wangaratta and Warringal Private Hospitals
-
NSW (2): Kareena Private and Strathfield Private Hospitals
-
QLD (3): John Flynn Private, Nambour Selangor Private and Noosa Hospital
-
WA (1): Joondalup Health Campus
| State | Number of Hospitals | Example Hospitals | Contracting Healius Entity | Term |
|---|---|---|---|---|
| VIC | 7 | Peninsula, Warringal, Shepparton | Healius Pathology Pty Ltd | 2–5 years |
| QLD | 3 | John Flynn, Noosa, Nambour Selangor | Healius Pathology Pty Ltd | 2–5 years |
| NSW | 2 | Kareena, Strathfield | Healius Pathology Pty Ltd | 2–5 years |
| WA | 1 | Joondalup Health Campus | Healius Pathology Pty Ltd | 2–5 years |
Why hospital pathology contracts matter to investors
Hospital pathology involves pathology services carried out for both public and private patients within hospital settings. As the incumbent provider, Healius already delivers these services across the 13 Ramsay hospitals.
For Healius, transitioning approximately $45m of annual revenue into standardised two to five year terms. It is important to note this represents continuation of existing revenue rather than incremental growth, and the figure remains contingent on continued demand.
Healius lifted its FY2026 earnings guidance to a Group Underlying EBITDA range of $259.0m-$264.0m, even as pathology volume headwinds and an indexation freeze on pathology funding continued to weigh on the division.
Continuity of a long-standing relationship
The renewal reflects Healius’ standing as a trusted incumbent pathology provider to Ramsay. By moving existing arrangements into a single national framework, both parties maintain continuity of service while formalising the commercial relationship.
Paul Anderson, Managing Director & CEO, Healius Limited
“We are honoured that Ramsay Health Care has renewed its pathology arrangements with Healius and are delighted to continue our work with Ramsay to deliver timely, consistent, quality pathology services to meet the needs of Ramsay hospital practitioners and patients.”
For over 35 years, Healius has been one of Australia’s leading healthcare companies. Through its footprint of centres and its 8,000+ employees, the company provides Australia-wide specialty pathology services to consumers and their referring practitioners.
The next major ASX story will hit our subscribers first
What happens next
The national agreement framework takes effect on 1 July 2026, with pathology services continuing uninterrupted at all 13 hospitals. The initial terms of between two and five years provide a multi-year runway of expected revenue across the four-state footprint.
Investors should note the revenue caveat. The approximately $45m in expected annual revenue is based on continued customer demand consistent with no significant changes in economic conditions. As actual results may differ from forward-looking expectations, undue reliance should not be placed on the figure.
Stay Ahead on Healthcare News Before the Market Moves
Big News Blast delivers FREE breaking ASX healthcare alerts straight to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 active subscribers are already getting the full picture the moment news breaks. Click the “Free Alerts” button at StockWire X to make sure the next market-moving announcement lands with you first.